American Society of Hematology

Fig. 1.

$Fig. 1. Progression-free survival (PFS) and overall survival (OS) of 81 patients with relapsed and refractory multiple myeloma, characterized by their TNF-α–238A/G and TNF-α–308A/G polymorphism status. / PFS was calculated from the start of thalidomide therapy to disease progression or death from any cause. At the start of thalidomide treatment, the drug was administered at a dose of 100 mg daily, following a weekly dose increment of 100 mg daily, for a final dose of 400 mg daily beginning at day 22.$

Progression-free survival (PFS) and overall survival (OS) of 81 patients with relapsed and refractory multiple myeloma, characterized by their TNF-α–238A/G and TNF-α–308A/G polymorphism status.

PFS was calculated from the start of thalidomide therapy to disease progression or death from any cause. At the start of thalidomide treatment, the drug was administered at a dose of 100 mg daily, following a weekly dose increment of 100 mg daily, for a final dose of 400 mg daily beginning at day 22.

This Feature Is Available To Subscribers Only